Chemotherapy Treatment Taxol Ineffective In Treating HER-2 Negative Breast Cancer, NEJM Study Says

The chemotherapy treatment paclitaxel, sold by Bristol-Myers Squibb under the brand name Taxol, is ineffective at treating HER-2 negative breast cancer, the most common form of the disease, according to a study published Thursday in the New England Journal of Medicine, the AP/Google.com reports. [click link for full article]

More: continued here

Filed under: Breast Cancer on October 20th, 2007